207 results on '"Kahlert, Johnny"'
Search Results
2. Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study
3. 10-Year Cardiovascular Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus
4. Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark
5. Human papillomavirus genotypes and risk of persistence and progression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2
6. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus–vaccinated and unvaccinated women: a population-based cohort study
7. Time trends in the clinical management of cervical intraepithelial neoplasia grade 2: A Danish register‐based study.
8. Clinical course of cervical intraepithelial neoplasia grade 2: a population-based cohort study
9. Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project
10. Everolimus-Eluting Versus Biolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus
11. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial)
12. Long-Term Risk of Developing Dementia After Electroconvulsive Therapy for Affective Disorders
13. Long‐term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes.
14. Changes in Body Mass and Organ Size during Wing Moult in Non-Breeding Greylag Geese Anser anser
15. Repeated Grazing of a Salt Marsh Grass by Moulting Greylag Geese Anser anser: Does Sequential Harvesting Optimise Biomass or Protein Gain?
16. Untreated cervical intraepithelial neoplasia grade 2 and subsequent risk of cervical cancer: population based cohort study.
17. Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial
18. Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial
19. The temporal and age‐dependent patterns of hysterectomy‐corrected cervical cancer incidence rates in Denmark: a population‐based cohort study
20. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent.
21. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared With the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial
22. Isotopic Evidence for Endogenous Protein Contributions to Greylag Goose Anser anser Flight Feathers
23. TCT-158 The Impact of Sex and Age on Long-Term Outcome After Percutaneous Coronary Interventions: A Pooled Analysis of the Randomized Controlled SORT OUT Trials
24. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38: 1089–1098
25. Global epidemiology of hysterectomy: possible impact on gynecological cancer rates
26. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study
27. Cervical intraepithelial neoplasia grade 2:Assessment of risks associated with conservative management
28. Opportunities and challenges for near real time monitoring (NRTM) of vaccine exposures and outcomes in the participating databases of the ADVANCE consortium
29. Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study.
30. Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent.
31. Response of breeding waders to agri-environmental schemes may be obscured by effects of existing hydrology and farming history
32. Outcomes After Revascularization With a Polymer-Free Biolimus-Eluting BioFreedom Stent or a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT IX Trial
33. Impact of diabetes on 1‐year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial.
34. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention:A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial)
35. 1-year rehospitalization after percutaneous coronary intervention:a retrospective analysis
36. Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial.
37. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
38. Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post‐authorization safety cohort study conducted in Europe and in the United States.
39. Trends in Hysterectomy Incidence Rates During 2000–2015 in Denmark: Shifting from Abdominal to Minimally Invasive Surgical Procedures.
40. Preterm Birth Following Active Surveillance vs Loop Excision for Cervical Intraepithelial Neoplasia Grade 2.
41. Factors affecting escape behaviour in moulting Greylag Geese Anser anser
42. Very Late Stent Thrombosis after Revascularization with Biodegradable Polymer Drug-Eluting Stents. From the SORT OUT VII Trial
43. Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII trial
44. TCT-278 Five-Year Outcomes After Revascularization With the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent or the Biodegradable Polymer Biolimus-Eluting Nobori Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT VII Trial
45. TCT-151 Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared With the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial
46. Trends in hysterectomy‐corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise?
47. Assessing the current feces identification method of the European otter Lutra lutra.
48. ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example.
49. Statin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study.
50. Two-year outcomes after revascularization with a biodegradable polymer ultra-thin strut sirolimus eluting stent and a biodegradable polymer biolimus-eluting stent. From the SORT OUT VII trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.